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Previewstranslation adds to our understanding
of cancer cellular metabolism. While
Skrtic et al. describe a dependency for
ribosomal translation and oxidative
phosphorylation in leukemia cells, the
Warburg hypothesis, a cornerstone of
cancer cellular metabolism, postulates
that cancer cells, unlike normal cells,
favor glycolysis for energy production,
even under aerobic conditions (Warburg,
1956). This reprogramming of energy
metabolism in cancer cells is now consid-
ered to be a distinct hallmark of cancer
cells (Hanahan and Weinberg, 2011; Hsu
and Sabatini, 2008; Luo et al., 2009). The
shift in cancer cell metabolism termed
‘‘aerobic glycolysis’’ may be partially an
adaptation to lower oxygen levels in
tumors, but may also be a direct con-
sequence of activation of certain onco-
genes such as MYC and RAS (Hsu and
Sabatini, 2008). In leukemia, inhibition of
fatty acid oxidation was recently shown
to sensitize leukemia cells to apoptosis
induction, but whether this finding is
linked to pathways affected by tigecycline
remains to be elucidated (Samudio et al.,
2010). The full relationship between
dependencies on mitochondrial metabo-556 Cancer Cell 20, November 15, 2011 ª20lism and glycolytic flux in leukemia cells
remains to be determined, but both repre-
sent attractive therapeutic targets for the
treatment of cancer.
Tigecycline is an FDA-approved drug
with known pharmacokinetics and
toxicity, facilitating preclinical studies.
The authors administered the drug to
mice engrafted with primary AML cells
and found a reduction in the leukemic
burden relative to controls, which demon-
strates that AML cells are therapeutically
accessible in vivo. Interestingly, com-
bining tigecycline with daunarubicin,
a cytotoxic drug in clinical use for AML,
had an additive or synergistic antileu-
kemic effect, suggesting that combining
the two should be considered for future
clinical trials. Similar results were ob-
tained for the combination of tigecycline
with Ara-C, another cytotoxic chemother-
apeutic agent in routine use for the treat-
ment of AML. Since tigecycline is already
used in patients as an antimicrobial, and
the toxicity profile is known, clinical trials
in AML could be initiated expeditiously
to determine the efficacy of tigecycline
for the treatment of this challenging
disease.11 Elsevier Inc.REFERENCES
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Constitutive activation of NF-kB signaling can promote oncogenesis, providing a rationale for anticancer
strategies that inhibit NF-kB signaling. Two recent publications in Genes & Development provide evidence
that, in contexts where prosurvival signals derive from other oncogenes, NF-kB activity instead enhances
sensitivity to cytotoxic chemotherapy, thereby exerting a tumor-suppressor function.The nuclear factor-kB (NF-kB) signaling
cascade is a major transducer of external
signals, controlling the expression of
a broad range of genes involved in cellsurvival, growth, stress response, and
inflammation (Hayden and Ghosh, 2008).
NF-kB signaling is tightly regulated and
aberrant activation of this pathway hasbeen associated with the pathogenesis
of solid tumors (Ben-Neriah and Karin,
2011). Recent studies have shown that B
cell lymphomas frequently harbor genetic
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Previewsmutations in NF-kB pathway components
resulting in constitutive, and presumably
oncogenic, NF-kB signaling by establish-
ing a prosurvival phenotype (Staudt,
2010). Taken together, these findings
have identified NF-kB as a critical player
in cancer development, creating a solid
rationale for the development of antitumor
therapies that inhibit NF-kB signaling.
However, two recent studies provide
compelling evidence that functional
NF-kB signaling is required for inducing
cytotoxic drug-mediated senescence in
tumors with a particular genetic makeup
(Chien et al., 2011; Jing et al., 2011) and
thus suggest a more complex role for
NF-kB in oncogenesis. The implication
of these findings is that inhibition of
NF-kB signaling would reduce chemo-
sensitivity instead of promoting cell death
in such tumors. These studies underscore
the importance of determining the con-
text dependency of NF-kB-mediated
functions when using NF-kB inhibitors.
The common starting point of these
two studies was the phenomenon that
cytotoxic chemotherapy can induce
tumor cell senescence as a mechanism
to halt tumor growth (Schmitt et al.,
2002; Kuilman et al., 2010). Therapy-
induced senescence exhibits a senes-
cence-associated secretory phenotype
(SASP) characterized by a strong cyto-
kine response that acts in an autocrine
feedback loop to achieve growth arrest
and attracts immune cells that eliminate
senescent cells (Coppe´ et al., 2008; Kuil-
man and Peeper, 2009). The different ex-
perimental strategies followed by these
studies both led to the identification of
NF-kB signaling as the major mediator of
the SASP. Intriguingly, the results suggest
that NF-kB pathway inhibition is contrain-
dicated in genetically defined cancer
subtypes in which NF-kB activation has
no primary role in prosurvival, but that
instead require a functional NF-kB path-
way for enhancing chemosensitivity.
Chien et al. identified the NF-kB subunit
p65 (RelA) bound abundantly to senes-
cent chromatin in a global proteomics
analysis and confirmed its transcriptional
activity. Whole genome gene expression
profiling (GEP) studies revealed that an
array of known NF-kB target genes,
including SASP components, failed to be
induced in p65 knockdown cells that
were activated to senesce. These results
suggested that NF-kB controls the tran-scriptional program mediating cellular
senescence. Chien et al. then developed
a mouse lymphoma model in which p65
can be knocked-down inducibly. Murine
lymphomas constitutively expressing
Myc and Bcl2 oncogenes undergo
senescence in response to cytotoxic
chemotherapy. A cytotoxic drug treat-
ment activated NF-kB and induced a
senescence response in p65-proficient,
but not p65-deficient lymphomas, dem-
onstrating that silencing NF-kB activity
impairs the senescence response to
chemotherapy in this in vivo model.
Consistently, p65-proficient tumors re-
gressed in response to cytotoxic drugs,
while p65 knock-down rendered tumors
unresponsive. Thus, in this particular con-
text in which apoptosis is suppressed by
constitutive BCL2 expression, inhibition
of NF-kB activity has the unwanted effect
of promoting cytotoxic drug resistance.
Jing et al. pursued a different approach
by first performing a GEP analysis on
tumors arising in the Em-myc non-
Hodgkin lymphoma mouse model that
were retrovirally transduced with BCL2
to block apoptosis and subsequently
exposed to cytotoxic agents. They found,
in accordance with markedly elevated
NF-kB activity upon treatment, that the
expression of NF-kB-controlled cytokines
characteristic of the SASP was strongly
upregulated in the lymphomas. By
functionally ablating the NF-kB pathway,
Jing et al. then demonstrated in vitro
and in vivo, that the observed therapy-
induced senescence in the lymphoma
cells indeed depended on NF-kB activity.
To determine the extent to which acti-
vated NF-kB contributed to therapy-
induced senescence, the panel of Em-
myc mouse lymphomas was separated
into those with high and low NF-kB
activity. Since strong NF-kB activity is
thought to be oncogenic by upregulating
a prosurvival program, they expectedly
observed that tumors with high NF-kB
activity were resistant to chemotherapy,
while those with low NF-kB activity were
sensitive. Indeed, the NF-kB high group
showed much stronger expression of
BCL2 compared to NF-kB low tumors.
When they then ectopically expressed
BCL2 in tumors of both groups, all tumors
were chemoresistant, independent of
NF-kB activity. Taken together, it appears
that when the antiapoptotic function of
NF-kB is replaced by other prosurvivalCancer Cell 20, Noncogenes, the role of NF-kB in therapy-
induced senescence can be unleashed
(Figure 1).
Finally, Jing et al. convincingly argue
that the observed results may have direct
implications for therapy strategies aimed
at genetically distinct subtypes of the
most common type of human non-
Hodgkin lymphomas, diffuse large B cell
lymphoma (DLBCL). The major DLBCL
subtypes are activated B cell-type (ABC)
DLBCL and germinal center B cell-type
(GCB) DLBCL that differ in their spectrum
of genetic alterations (Rui et al., 2011).
While many ABC-DLBCL have mutations
in various genes encoding NF-kB path-
way components leading to deregulated
NFkB signaling, such mutations are rare
in GCB-DLBCL (Staudt, 2010). Con-
versely, a sizable fraction of GCB-DLBCL
is associated with recurrent chromo-
somal translocations that result in de-
regulated BCL2 expression; ABC-DLBCL
also expresses high amounts of BCL2
likely due to constitutive NF-kBactivation.
Importantly, GCB-DLBCL has a markedly
better clinical outcome following immu-
nochemotherapy compared with ABC-
DLBCL. This striking resemblance of the
genetic and clinical characteristics of
these DLBCL subtypes to the situation
encountered in their lymphoma mouse
model led Jing et al. to interrogate
a GEP data set of human DLBCL that
were treated with standard immunoche-
motherapy. By correlating an established
NF-kB ‘‘signature’’ in the GEP data with
progression-free survival, they observed
that BCL2-overexpressing GCB-DLBCL
tumors with high NF-kB activity showed
a more favorable prognosis after chemo-
therapy compared to tumors with low
NF-kB activity. As predicted, NF-kB
activity did not correlate with survival
in patients with ABC-DLBCL. While it
remains to be proved experimentally
whether the more favorable clinical
course of GCB-DLBCL compared with
ABC-DLCBL in humans is mechanis-
tically linked to an NF-kB-mediated,
therapy-induced senescence in tumor
cells, the elegant studies by Chien et al.
(2011) and Jing et al. (2011) provide new
light on the context-dependent roles of
NF-kB in oncogenesis and therapy.
The opposing roles of NF-kB in onco-
genesis, promoting tumorigenesis on
one hand and mediating therapy-induced
senescence on the other (see Figure 1),ovember 15, 2011 ª2011 Elsevier Inc. 557
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Figure 1. Model for the Context-Dependent Opposing Roles of NF-kB Signaling in Cancer Development and Therapy
(A) In tumors with genetic mutations in NF-kB pathway components leading to constitutive NF-kB signaling, the prosurvival BCL2 oncogene is upregulated.
In these tumors, such as ABC-DLBCL, NF-kB inhibitors are beneficial as they counteract the oncogenic function of NF-kB and would promote tumor cell death.
(B) In tumors where the prosurvival signal derives fromNF-kB-independentBCL2 overexpression, a functional NF-kBpathway is required tomediate the therapy-
induced senescence response by activating the transcription of genes of SASP. In this scenario, such as in GCB-DLBCL, NF-kB inhibitors are detrimental as they
interfere with the senescence response that would normally promote tumor cell death.
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Previewshave significant therapeutic implications.
First, the findings imply that the use of
NF-kB inhibitors in the clinic requires
thorough assessment, since NF-kB inhi-
bition could interfere with the cytotoxicity
of standard chemotherapy in combi-
nation therapies. Second, Jing et al.
(2011) observed that ectopic activation
of NF-kB in mouse lymphomas with low
NF-kB activity enhances therapy-induced
senescence; these results provide a ratio-
nale for the development of therapeutic
strategies that enhance chemosensitivity
by activating NF-kB concomitantly with
cytotoxic chemotherapy. Third, eluci-
dating the precise mechanisms of NF-kB
in oncogenesis versus therapy-induced
senescence could lead to the identifica-
tion of crucial downstream components
of NF-kB that mediate chemosensitivity,558 Cancer Cell 20, November 15, 2011 ª20with the eventual goal of developing
strategies to boost senescence in tumors
where NF-kB’s oncogenic function domi-
nates. The findings by Chien et al. (2011)
and Jing et al. (2011) provide important
new insights into the complexity of
NF-kB signaling in cancer cells. In future
studies, this knowledge will likely be ex-
ploited for the development of specific,
more effective anticancer therapies.REFERENCES
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